PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen, Belgium) announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA (“Merck”).

新闻稿-2024年5月6日07:00 CEST Biocartis和默克公司合作改善中东和北非（MEA）地区患者获得个性化医疗的机会Biocartis（比利时梅切伦）宣布扩大与默克公司（Merck KGaA）的附属公司默克Serono Middle East和默克沙特有限公司（Merck Saudi Ltd.）的合作。

The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region. Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated incidence of more than 1.9 million new cases annually. An estimated 904 thousand deaths from CRC occur worldwide every year, making it the second most common cause of death from cancer.1 Understanding an individual patient’s biomarker status is key to support timely treatment decision-making in metastatic colorectal cancer (mCRC).2 Treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies have shown to improve outcomes in patients with RAS wild-type mCRC3,4 and have become standard of care for RAS wild-type mCRC.5 RAS biomarker testing is cumbersome and not readily available in all parts of the world.

该合作旨在改善中东和北非（MEA）地区患者获得RAS生物标志物检测的机会。大肠癌（CRC）是全球第三大常见癌症，估计每年新发病例超过190万。据估计，全世界每年有90.4万人死于结直肠癌，使其成为癌症死亡的第二大常见原因[1]。了解个体患者的生物标志物状态是支持转移性结直肠癌（mCRC）及时治疗决策的关键[2]。抗表皮生长因子受体（EGFR）单克隆抗体治疗已显示可改善RAS野生型mCRC3,4患者的预后，并已成为RAS野生型mCRC的标准治疗方法[5]。RAS生物标志物检测繁琐，世界各地都不容易获得。

The Idylla™ KRAS Mutation Test and Idylla™ NRAS-BRAF Mutation Test are highly performant6 Tests that rapidly determine the RAS biomarker status in mCRC tumor tissue samples. Due to the ease-of-use of the Biocartis Idylla™ Platform, the Tests can be deployed in any user setting and in turn aid patient access to biomarker testing globally.

Idylla™KRAS突变测试和Idylla™NRAS-BRAF突变测试是高性能的6项测试，可快速确定mCRC肿瘤组织样本中的RAS生物标志物状态。由于Biocartis Idylla™平台易于使用，因此可以在任何用户环境中部署测试，从而帮助患者在全球范围内进行生物标志物测试。

Roger Moody, Chief Executive Officer of Biocartis, commented: “We are thrilled to announce the expansion of our collaboration with Merck in the Middle East and North Africa (MEA) region, aimed at advancing healthcare solutions and ensuring timely and accurate diagnostic.

Biocartis首席执行官罗杰·穆迪（Roger Moody）评论道：“我们很高兴宣布扩大与默克公司在中东和北非（MEA）地区的合作，旨在推进医疗保健解决方案，确保及时准确的诊断。